Internal Medicine, Endocrinology, Diabetes, & Metabolism · Jacksonville, FL
NPI
1164742144
Since 2010
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
4203 Belfort Rd, Suite 315
Jacksonville, FL, 32216
Phone (904) 450-6860
Groups this clinician bills Medicare through
Medicare paid, 2024
$43K
1,732 services
Medicare patients, 2024
270
Average age 71
Drug cost, 2024
$4.1M
5,146 prescriptions
Company payments, 2025
$647
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nitika Malhotra was code 99214 (office e&m - established), 231 times for 176 patients. In total Nitika Malhotra billed 1,732 services in 14 codes, and Medicare paid $43K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-03-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 231 | 176 | $64.01 | $15K |
| 99214 Office E&M - Established | Facility | 172 | 151 | $75.10 | $13K |
| 95251 Test - Miscellaneous | Facility | 106 | 63 | $26.22 | $2,779 |
| 95251 Test - Miscellaneous | Office | 99 | 57 | $22.08 | $2,186 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 59 | 55 | $12.81 | $756 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 47 | 46 | $12.26 | $576 |
| 99204 Office E&M - New | Office | 23 | 23 | $93.40 | $2,148 |
| 99205 Office E&M - New | Office | 14 | 14 | $116.36 | $1,629 |
| 99205 Office E&M - New | Facility | 11 | 11 | $110.35 | $1,214 |
| 99204 Office E&M - New | Facility | 11 | 11 | $104.76 | $1,152 |
| 76536 Ultrasound - Nonspecific | Office | 11 | 11 | $15.03 | $165 |
By year: 2022 $89K for 3,533 services; 2023 $70K for 2,879 services; 2024 $43K for 1,732 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 27 | 25 | $8.11 | $219 |
| 82962 Clinical Chemistry | 24 | 22 | $2.94 | $70.62 |
Medicare prescription drug claims, 2024
In 2024, the drug Nitika Malhotra prescribed most often to Medicare patients was Ozempic (Semaglutide), with 774 prescriptions and refills. In total Nitika Malhotra wrote 5,146 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 774 | 1,246 | 153 | $1.2M |
| Jardiance Empagliflozin | 464 | 926 | 126 | $538K |
| Tresiba Flextouch U-200 Insulin Degludec | 414 | 806 | 109 | $440K |
| Synthroid Levothyroxine Sodium | 380 | 775 | 77 | $33K |
| Mounjaro Tirzepatide | 285 | 311 | 48 | $324K |
| Trulicity Dulaglutide | 199 | 251 | 41 | $241K |
| Tresiba Flextouch U-100 Insulin Degludec | 155 | 335 | 43 | $80K |
| Metformin Hcl Generic | 153 | 438 | 58 | $887 |
| Levothyroxine Sodium Generic | 137 | 359 | 41 | $1,421 |
| Farxiga Dapagliflozin Propanediol | 130 | 240 | 36 | $132K |
| Novolog Flexpen Insulin Aspart | 102 | 182 | 36 | $23K |
| Januvia Sitagliptin Phosphate | 94 | 166 | 22 | $91K |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | 91 | 130 | 16 | $77K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 82 | 177 | 35 | $7,108 |
| Methimazole Generic | 80 | 191 | 17 | $701 |
Brand drugs: 3,990 claims; generic drugs: 785 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nitika Malhotra $647 ($647 in general payments such as food, travel and fees) from 12 companies. The largest payer was Sequel Med Tech, LLC with $151.
| Company | Payments | Amount |
|---|---|---|
| Sequel Med Tech, LLC | 8 | $151 |
| Novo Nordisk Inc NVO | 4 | $142 |
| Ascendis Pharma Endocrinology Inc ASND | 1 | $92.98 |
| Abbott Laboratories ABT | 4 | $63.59 |
| Insulet Corporation PODD | 2 | $38.57 |
| Xeris Pharmaceuticals, Inc. | 2 | $35.88 |
| Ascensia Diabetes Care Us Inc. | 1 | $25.13 |
| Corcept Therapeutics CORT | 1 | $25.11 |
| Amneal Pharmaceuticals LLC AMRX | 1 | $22.91 |
| Neurocrine BioSciences, Inc. NBIX | 1 | $19.52 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.